Explore Our Affordable Courses

Click Here

Production-linked incentive (PLI) scheme for bulk drugs (APIs)

Context:

  • The production-linked incentive (PLI) scheme for bulk drugs (APIs) has boosted local production of some key APIs, However, it would take at least 5-7 more years before India can see tangible results.

What is API?

  • Active Pharmaceutical Ingredient (API) is the biologically active component of a drug product (tablet, capsule, cream, injectable) that produces the intended effects.

Data: India’s Import from China

  • ​Currently, China is the global leader in the production and export of APIs, which is around 20 percent of the world’s API production.
  • The Indian pharmaceutical industry is the 3rd largest in the world by volume and 14th in value. India contributes 3.5% of total drugs and medicines exported globally.
  • However, India significantly depends on importing some of the basic raw materials, viz., bulk drugs used to produce the finished dosage formulations. 
  • India imports bulk drugs largely for economic considerations. Bulk drugs accounted for  around 63% of the total pharmaceutical imports in the country.
  • Data from the Pharmaceutical Exports Promotion Council (Pharmexcil) shows India imported $3.18 billion worth of APIs and intermediates from China in 2022-23, up 1.74 percent from the previous year. 
  • In 2021-22, India had imported $3.12 billion worth of APIs and intermediates from China, which was up 19.5 percent from 2020-21.
  • Therefore, the growth rate has slowed, but the imports continue at similar levels.
  • On the other hand, India’s imports of bulk drugs and intermediates worldwide (overall) came down by 4.54 percent to $4.5 billion. 
  • This is in contrast to the previous year when they had grown by almost 23 percent to $4.7 billion.

Production-linked incentive

Production-linked incentive (PLI) scheme for bulk drugs (APIs)

  • The pharmaceuticals department rolled out a PLI scheme for bulk drugs with an outlay of Rs 6,940 crore.
  • Objective: The scheme intends to boost domestic manufacturing of identified KSMs, Drug Intermediates and APIs by attracting large investments in the sector, thereby reducing India’s import dependence on critical APIs.
  • Scope: Under the Scheme, financial incentives shall be given based on sales made by selected manufacturers for 41 products.
  • The scheme offers incentive rates of 20 percent for the first year, 15 percent for the fifth year, and 5 percent for the sixth year.
  • As of February, around 22 projects to make key APIs came up under the PLI scheme. These units have a total installed capacity above 33,000 tonnes.

Source: Business Standards

 

To get PDF version, Please click on "Print PDF" button.

Need help preparing for UPSC or State PSCs?

Connect with our experts to get free counselling & start preparing

Download October 2024 Current Affairs.   SRIJAN 2025 Program (Prelims+Mains) !     Current Affairs Plus By Sumit Sir   UPSC Prelims Test Series 2025

THE MOST
LEARNING PLATFORM

Learn From India's Best Faculty

      

Download October 2024 Current Affairs.   SRIJAN 2025 Program (Prelims+Mains) !     Current Affairs Plus By Sumit Sir   UPSC Prelims Test Series 2025

Quick Revise Now !
AVAILABLE FOR DOWNLOAD SOON
UDAAN PRELIMS WALLAH
Comprehensive coverage with a concise format
Integration of PYQ within the booklet
Designed as per recent trends of Prelims questions
हिंदी में भी उपलब्ध
Quick Revise Now !
UDAAN PRELIMS WALLAH
Comprehensive coverage with a concise format
Integration of PYQ within the booklet
Designed as per recent trends of Prelims questions
हिंदी में भी उपलब्ध

<div class="new-fform">







    </div>

    Subscribe our Newsletter
    Sign up now for our exclusive newsletter and be the first to know about our latest Initiatives, Quality Content, and much more.
    *Promise! We won't spam you.
    Yes! I want to Subscribe.